Latest news with #NEC
USA Today
3 hours ago
- Sport
- USA Today
Tiger Woods' 'Shot in the Dark' still resonates at Firestone Country Club 25 years later
Twenty-five years after Tiger Woods' 'Shot in the Dark,' all Hal Sutton remembers are the beams of light. Sutton believes it may have been from cars in the distance as the 2000 World Golf Championships-NEC Invitational was nearing conclusion. One long-time volunteer recalls trucks being pulled into the parking lot at Firestone Country Club for illumination. Behind the 18th green, a light pole stood beside the CBS broadcast tower housing Jim Nantz and Ken Venturi. Network cameras had irises wide open, deceiving viewers of the blackness at 8:25 p.m. After a nearly three-hour rain delay, all were pushing to finish. Woods' playing partner, Sutton, had a plane waiting to take him to Jamaica for a match in 'Shell's Wonderful World of Golf' the next day. Woods battled flu-like symptoms in the final round, his fever breaking on the fourth hole. Woods came to 18 with a 10-stroke lead, so the only thing in doubt was where Sutton would end up on the earnings list. Facing a chip from behind the green that he had to walk off to gauge, Sutton recently said by phone, 'I had never been part of something that dark.' But Woods didn't need to see. Channeling his childhood days playing in the twilight with his father, Woods struck an 8-iron from 167 yards that landed two feet from the pin. After locating the ball, the gallery erupted. To help him sink the birdie putt, fans pulled out cigarette lighters. 'It was just like you were at a concert, wanting to have another encore,' then-tournament director Tom Strong said. Ryan Lewis takes on 'The Monster': The Monster 16th at Firestone South: One hacker's adventure playing a 667-yard par-5 'The cool effect of it all was when the putt was on the way, all the flashbulbs going off. It created for golf a paparazzi moment that you never see in the heat of the battle,' Nantz said. 'There was a long list of jaw-dropping moments in Tiger's career, but this is on the very short list of the ones that defy explanation. That shot. The hole-out at 16 at Augusta in 2005 where the ball hung on the lip. There's a long list of almost ridiculous achievements and accomplishments by Tiger. But this is on that ultra-exclusive special-special list of things you can never explain.' What readers remember: Readers share memories of Tiger Woods' 'Shot in the Dark' at Firestone Country Club in 2000 The 'Shot in the Dark' remains arguably the most iconic moment in the 70-year history of professional golf at Firestone, where Woods has won eight times. Strong, now a retired PGA Tour official living in Wisconsin, puts it in his top three in Akron, with Woods' seven-hole playoff victory over Jim Furyk in the 2001 NEC Invitational his No. 1. Nantz added Jose Maria Olazabal's 12-shot victory in the 1990 NEC World Series of Golf, Greg Norman chipping in from the right of the 18th green to win a 1995 NEC playoff with Nick Price and Billy Mayfair and Jack Nicklaus vs. Lee Elder, who went shot for shot for four playoff holes before Nicklaus won the 1968 American Golf Classic. With Nicklaus rallying from a five-stroke deficit and Frank Beard eliminated earlier in sudden death, that ending has been called one of the most exciting in televised golf history. But for most golf fans, those do not remain talking points. The spot from where Woods hit the 'Shot in the Dark' in the first cut right of the fairway has become a destination. During the June 18 pro-am before the $3.5 million Kaulig Companies Championship, amateurs and caddies took pictures. There are divots from those who have tried recreating Woods' magic. 'Who else could have done that? One of the greatest athletes of the century, an incredible athlete at the peak of his skills doing something absolutely unfathomable,' said Michael Weinreb, a journalist, novelist and screenwriter who pens 'Throwbacks' on Substack. The 'Shot in the Dark' was Weinreb's final article for the Beacon Journal before he left to attend graduate school. 'I distinctly remember that sound of that ball landing on the green, that plunk of the ball,' Weinreb said by phone from his home in Oakland. 'It almost felt like you were alone because it was so dark out. I will never forget that feeling — 'This is something I will remember 25 years from now' — and I do. 'It's one of those moments that gives you chills just thinking about it.' Reader memories: Remembering Tiger Woods' 'Shot in the Dark' at Firestone Country Club in 2000 Woods, 49, has amassed 82 career victories on the PGA Tour, including 15 majors. At the 2000 NEC, he was coming off a playoff victory over Bob May in the PGA Championship, had won the U.S. Open at Pebble Beach by 15 shots and the Open Championship at St. Andrews by 8 strokes. After eight official victories that year, he would complete the 'Tiger Slam' in April with a two-shot triumph at the Masters. Ernie Els was runner-up at two of those, the U.S. and British Opens. 'That's one of those moments that Tiger Woods brought to this place,' Els said June 18 of the 'Shot in the Dark.' 'So many moments just on this venue.' Nantz broadcast tournaments from Akron for 33 years and remains nostalgic for Firestone, which last hosted a PGA Tour event in 2018. His memories of the 'Shot in the Dark' are more vivid than his sight was that night. 'I could not make out anyone back in the fairway,' Nantz said by phone from his home at Pebble Beach. 'It was that almost boomerang-shaped green and that back hole location is extremely narrow. I never could follow the ball in flight. I remember this thing coming in and once it landed, it was just jaw-dropping. I could still barely make out the golf ball. It was as if he had GPS'd the shot and struck it with his eyes closed because that's basically what it felt like in person.' Sutton, 67, living in Columbus, Texas, in retirement, won 14 times on the PGA Tour. He admitted he initially wasn't wild about the rush to the clubhouse. Strong recalled the rules officials wanting to stop at 16 before getting word the final group wanted to finish. 'He had a [big] lead on me. Who knows what I could have made in the dark,' Sutton said by phone from his hometown of Shreveport, La., where he was visiting his father. 'He wanted to go play and I was like, 'Uh, I'm the only one who could lose anything here. He can't play that bad on the hole.' 'We agreed and he makes birdie, and I made par. It all worked out fine and it was part of history.' Sutton nearly holed his chip, easing his anxiety. Always naming Firestone among his favorites because 'it's a great ball-strikers course,' Sutton found consolation in his one-shot victory over Woods in the 2000 Players Championship at TPC Sawgrass. Sutton counts that among his career highlights, along with beating Nicklaus in the 1983 PGA Championship at Riviera Country Club. When it was suggested that Woods won basically everything in 2000, Sutton said, 'Except TPC. So I was with him at two iconic moments of that year. Kind of fun to recall both of those moments, really. One I was the winner and one he trounced us all.' Sutton said he was never bothered by the massive galleries that followed Woods. 'That's what we dealt with every week. They were wanting to see history,' Sutton said. 'They thought Tiger was going to break all of Jack's records. 'The crowd to me was always like a frame to a picture. Actually, the crowd makes it easier in a way because it frames where you're trying to go.' Woods has not competed since July 2024 due to multiple surgeries, many after a horrific single-car accident in 2021 in Los Angeles. He turns 50 on Dec. 30, making him eligible for the PGA Tour Champions, which allows players to ride in carts. 'When he gets in a cart, he'll tear it up, absolutely,' Nicklaus said last month at the Memorial Tournament, per Golfweek. 'He'll win better than 50 percent of the tournaments he plays in, I think. You all know how good a player he is but, I mean, his work ethic is so good.' Els has been Woods' victim several times and watched his legendary shots, many at Firestone. Count Els among those who hope Woods can return to the Akron course he once dominated. 'He's just an amazing, phenomenal player,' Els said. 'Hopefully we'll see him out here next year or the year after that.'
Yahoo
a day ago
- Health
- Yahoo
Transgene completes initial screening in Phase II part of TG4050 vaccine trial
Transgene has completed the initial subject screening for the Phase II segment of its Phase I/II trial of individualised neoantigen therapeutic vaccine, TG4050, as a monotherapy in the adjuvant treatment of human papillomavirus (HPV)-negative squamous head and neck cancers. The vaccine is based on the myvac platform powered by its partner NEC's AI to enhance antigen selection. During the Phase I portion of the trial, all subjects treated with the vaccine remained disease-free post a minimum follow-up of two years, demonstrating clinical proof of principle. Translational data indicated that these subjects showed sustained T cell responses at 24 months. Meeting all trial endpoints, the findings were shared at the American Society of Clinical Oncology (ASCO 2025) annual meeting. The company anticipates completing the randomisation of all subjects in the Phase II part by the end of this year, after a second screening carried out post-surgery and adjuvant radiotherapy. Around 80 subjects who have completely responded to adjuvant therapy are expected to be enrolled and randomised in the Phase I/II trial. The first immunogenicity data from the Phase II part are projected to be available in the second half of 2026, with preliminary efficacy data anticipated in the second half of 2027. The trial is assessing the treatment benefits of the vaccine in individuals at risk of relapse. So far, 32 evaluable patients have been included in the Phase I part, with the Phase II continuing globally. Transgene chief medical officer Dr Emmanuelle Dochy said: 'Timely completion of first patient screening of the Phase II part of our Phase I/II trial is an important milestone for Transgene and brings us one step closer to providing a new treatment option for patients living with operable squamous head and neck cancer. 'With meaningful data readouts expected over the next two years, we are preparing to deliver important data for TG4050 and, at the same time, explore its wider potential. We are grateful to the patients, their families, investigators, and clinical staff whose commitment made this achievement possible.' "Transgene completes initial screening in Phase II part of TG4050 vaccine trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
2 days ago
- Business
- Yahoo
Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer
Phase I part showed 100% Disease-Free Survival (DFS) after a minimum of 2-year follow-up – providing clinical proof of principle for TG4050 Randomization of all patients expected to be completed by end 2025 First immunogenicity data of Phase II part expected in H2 2026 Preliminary efficacy data expected in H2 2027Strasbourg, France, June 19, 2025, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the completion of initial patient screening in the randomized multicenter Phase II part of its Phase I/II clinical trial with TG4050, an individualized neoantigen therapeutic vaccine, as a single agent in the adjuvant treatment of HPV-negative squamous head and neck cancers (NCT04183166). TG4050, Transgene's lead asset, is based on its proprietary myvac® platform and powered by NEC's cutting-edge AI capabilities designed to optimize antigen selection for individual patients. All patients treated with TG4050 in the Phase I part of the trial remained disease-free after a minimum of two years of follow-up, confirming clinical proof of principle. Translational data showed sustained T cell responses at 24 months in these patients. The results, which met all trial endpoints including safety, feasibility, immune activation and disease-free survival (DFS, defined as survival without recurrence or death for any cause), were presented in an oral presentation at the recent American Society of Clinical Oncology (ASCO 2025) annual meeting. Transgene expects to complete randomization of all patients in the Phase II part by the end of 2025, following a second screening of patients conducted after surgery and adjuvant (chemo)radiotherapy. These screenings represent key steps during which patients are evaluated to determine whether they meet the eligibility criteria to participate in the clinical trial. In total, approximately 80 patients with a complete response to adjuvant therapy are anticipated to be enrolled and subsequently randomized in the Phase I/II trial. First immunogenicity data from the Phase II part of the trial are expected to be available in H2 2026, and preliminary efficacy data are expected in H2 2027. Dr. Emmanuelle Dochy, MD, Chief Medical Officer of Transgene added: 'Timely completion of first patient screening of the Phase II part of our Phase I/II trial is an important milestone for Transgene and brings us one step closer to providing a new treatment option for patients living with operable squamous head and neck cancer. With meaningful data readouts expected over the next two years, we are preparing to deliver important data for TG4050 and at the same time explore its wider potential. We are grateful to the patients, their families, investigators, and clinical staff whose commitment made this achievement possible.' Dr. Alessandro Riva, CEO of Transgene commented: 'The positive results from the Phase I part of our TG4050 trial support the strong potential of our myvac® platform. The successful completion of the first screening of the randomized Phase II part in less than a year and ahead of schedule underscores the investigators' commitment to rapidly advance the development of TG4050. In the ongoing Phase II part of the trial, we have been able to scale efficiently, strengthen our manufacturing capabilities and operate with the agility needed to lead in a highly competitive and fast-moving myvac® individualized cancer vaccine platform can be applied across a range of solid tumors where in many cases a significant unmet medical need remains. Consequently, Transgene is starting initial preparations for a new Phase I trial in a second, undisclosed indication in an early treatment setting, with the aim to initiate the trial in Q4 2025.' *** Contacts Media: Investors & Analysts: Caroline Tosch Lucie Larguier Corporate and Scientific Communications Manager Chief Financial Officer (CFO) +33 (0)3 68 33 27 38 Nadege Bartoli communication@ Investor Relations Analystand Financial Communications Officer MEDiSTRAVA +33 (0)3 88 27 91 00/03 Frazer Hall/Sylvie Berrebi investorrelations@ + 44 (0)203 928 6900 transgene@ About TransgeneTransgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company's clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company's lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The portfolio also includes other viral-vector-based immunotherapies: TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the viral backbone. The Company also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities. With Transgene's myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner its proprietary platform Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic information about Transgene is available at: us on social media: X (formerly Twitter): @TransgeneSA — LinkedIn: @Transgene — Bluesky: @Transgene About myvac®myvac® is a viral vector (MVA – Modified Vaccinia Ankara) based, individualized immunotherapy platform that has been developed by Transgene to target solid tumors. myvac®-derived products are designed to stimulate the patient's immune system to recognize and destroy tumors using their own cancer specific genetic mutations. Transgene has set up an innovative network that combines bioengineering, digital transformation, established vectorization know-how and unique manufacturing capabilities. Transgene has been awarded 'Investment for the Future' funding from Bpifrance for the development of its platform myvac®. TG4050 is the first myvac®-derived product being evaluated in clinical trials. Click here to watch a short video on myvac®. About TG4050TG4050 is a clinical stage individualized immunotherapy being developed for solid tumors that is based on Transgene's myvac® technology and powered by NEC's longstanding artificial intelligence (AI) and machine learning (ML) expertise. This virus-based therapeutic vaccine encodes neoantigens (patient-specific mutations) identified and selected by NEC's Neoantigen Prediction System. The prediction system is based on more than two decades of expertise in AI and has been trained on proprietary data allowing it to accurately prioritize and select the most immunogenic is designed to stimulate the immune system of patients in order to induce a T-cell response that is able to recognize and destroy tumor cells based on their own neoantigens. This individualized immunotherapy is developed and produced for each patient. Positive data have been generated in the adjuvant setting of head and neck cancer (NCT04183166). A Phase II part is ongoing, Transgene is preparing an additional trial in a second indication, with aim to initiate the trial in Q4 2025. About the Phase I/II clinical trialTG4050 is being evaluated in a Phase I/II clinical trial for patients with HPV-negative head and neck cancers (NCT04183166). An individualized treatment is created for each patient after they complete surgery and while they receive adjuvant therapy. Half of the participants received their vaccine immediately after completing adjuvant treatment. The other half were given TG4050 as an additional treatment at the time of recurrence of the disease as an additional treatment to standard of care (SoC). This randomized study is evaluating the treatment benefits of TG4050 in patients who are at risk of relapse. In the Phase I part, thirty-two evaluable patients have been included. The Phase II part is ongoing internationally. Overall approximately 80 patients will be randomized in the trial. DisclaimerThis press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque') section of the Universal Registration Document, available on the AMF website ( or on Transgene's website ( Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. Attachment 20250619_Completion_EN
AFP
2 days ago
- Politics
- AFP
S. Korean population and ballot figures used to resurface baseless election fraud claims
"Choo Mi-ae was elected representative in Hanam-A district through voter fraud," declares the Korean-language caption of a graphic shared in a Facebook post on June 16, 2025. Choo, a six-term lawmaker and former justice minister, during the April 2024 general election (archived link). The post, however, questions the legitimacy of the vote. Superimposed text on the graphic reads: "You call this a country? A nation ruled by bandits!" It then lists purported voting figures from the district's Shinjang 1-dong "Total population: 6,950. Number of eligible voters: 6,467. Number of votes cast: 7,179." Image Screenshot of the false Facebook post, captured on June 17, 2025 The same graphic alleging voter fraud in , and has resurfaced since centre-left candidate Lee Jae-myung's resounding victory in South Korea's June 3 presidential election (archived link). "The problem is that the People Power Party chooses to ignore voter fraud, so what is the point of this evidence," read a comment on one of the posts. Another said: "It is evident that Choo Mi-ae's election was fraudulent." Official data from the South Korean government and the country's election watchdog, however, shows the figures used in the graphic are inaccurate. Population and voting data Information from the Ministry of Interior shows the total population of Shinjang 1-dong at the time of the April 2024 general election was 6,902 -- not 6,950 as claimed in the falsely shared graphic (archived link). According to South Korea's National Election Commission (NEC), the number of eligible voters in Shinjang 1-dong during the April 2024 general election was 7,179 -- not 6,467 (archived link). The NEC data also shows 4,719 votes were cast -- not 7,179. "Even if the number of ballots cast had exceeded the population of the neighbourhood, that would not constitute evidence of fraud," an NEC spokesperson told AFP on June 17. South Korea allows voters to cast their ballots outside their district of residence during early voting (archived link). "This means that non-residents can legally vote in a different area from where they reside, causing the number of votes cast in the district to exceed the number of residents," the spokesperson said. This misunderstanding has become a recurring theme in South Korean elections, especially among groups alleging electoral fraud. The NEC issued a statement on June 1 in response to separate allegations of election fraud in Buan County in the North Jeolla province, saying the number of votes corresponds to the total number of electors who cast their votes at ballot stations in the county, "not just those who reside in the area" (archived link). AFP has debunked multiple false claims alleging voter fraud in South Korean elections.
Yahoo
3 days ago
- Business
- Yahoo
Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer
Phase I part showed 100% Disease-Free Survival (DFS) after a minimum of 2-year follow-up – providing clinical proof of principle for TG4050 Randomization of all patients expected to be completed by end 2025 First immunogenicity data of Phase II part expected in H2 2026 Preliminary efficacy data expected in H2 2027Strasbourg, France, June 19, 2025, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the completion of initial patient screening in the randomized multicenter Phase II part of its Phase I/II clinical trial with TG4050, an individualized neoantigen therapeutic vaccine, as a single agent in the adjuvant treatment of HPV-negative squamous head and neck cancers (NCT04183166). TG4050, Transgene's lead asset, is based on its proprietary myvac® platform and powered by NEC's cutting-edge AI capabilities designed to optimize antigen selection for individual patients. All patients treated with TG4050 in the Phase I part of the trial remained disease-free after a minimum of two years of follow-up, confirming clinical proof of principle. Translational data showed sustained T cell responses at 24 months in these patients. The results, which met all trial endpoints including safety, feasibility, immune activation and disease-free survival (DFS, defined as survival without recurrence or death for any cause), were presented in an oral presentation at the recent American Society of Clinical Oncology (ASCO 2025) annual meeting. Transgene expects to complete randomization of all patients in the Phase II part by the end of 2025, following a second screening of patients conducted after surgery and adjuvant (chemo)radiotherapy. These screenings represent key steps during which patients are evaluated to determine whether they meet the eligibility criteria to participate in the clinical trial. In total, approximately 80 patients with a complete response to adjuvant therapy are anticipated to be enrolled and subsequently randomized in the Phase I/II trial. First immunogenicity data from the Phase II part of the trial are expected to be available in H2 2026, and preliminary efficacy data are expected in H2 2027. Dr. Emmanuelle Dochy, MD, Chief Medical Officer of Transgene added: 'Timely completion of first patient screening of the Phase II part of our Phase I/II trial is an important milestone for Transgene and brings us one step closer to providing a new treatment option for patients living with operable squamous head and neck cancer. With meaningful data readouts expected over the next two years, we are preparing to deliver important data for TG4050 and at the same time explore its wider potential. We are grateful to the patients, their families, investigators, and clinical staff whose commitment made this achievement possible.' Dr. Alessandro Riva, CEO of Transgene commented: 'The positive results from the Phase I part of our TG4050 trial support the strong potential of our myvac® platform. The successful completion of the first screening of the randomized Phase II part in less than a year and ahead of schedule underscores the investigators' commitment to rapidly advance the development of TG4050. In the ongoing Phase II part of the trial, we have been able to scale efficiently, strengthen our manufacturing capabilities and operate with the agility needed to lead in a highly competitive and fast-moving myvac® individualized cancer vaccine platform can be applied across a range of solid tumors where in many cases a significant unmet medical need remains. Consequently, Transgene is starting initial preparations for a new Phase I trial in a second, undisclosed indication in an early treatment setting, with the aim to initiate the trial in Q4 2025.' *** Contacts Media: Investors & Analysts: Caroline Tosch Lucie Larguier Corporate and Scientific Communications Manager Chief Financial Officer (CFO) +33 (0)3 68 33 27 38 Nadege Bartoli communication@ Investor Relations Analystand Financial Communications Officer MEDiSTRAVA +33 (0)3 88 27 91 00/03 Frazer Hall/Sylvie Berrebi investorrelations@ + 44 (0)203 928 6900 transgene@ About TransgeneTransgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company's clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company's lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The portfolio also includes other viral-vector-based immunotherapies: TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the viral backbone. The Company also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities. With Transgene's myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner its proprietary platform Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic information about Transgene is available at: us on social media: X (formerly Twitter): @TransgeneSA — LinkedIn: @Transgene — Bluesky: @Transgene About myvac®myvac® is a viral vector (MVA – Modified Vaccinia Ankara) based, individualized immunotherapy platform that has been developed by Transgene to target solid tumors. myvac®-derived products are designed to stimulate the patient's immune system to recognize and destroy tumors using their own cancer specific genetic mutations. Transgene has set up an innovative network that combines bioengineering, digital transformation, established vectorization know-how and unique manufacturing capabilities. Transgene has been awarded 'Investment for the Future' funding from Bpifrance for the development of its platform myvac®. TG4050 is the first myvac®-derived product being evaluated in clinical trials. Click here to watch a short video on myvac®. About TG4050TG4050 is a clinical stage individualized immunotherapy being developed for solid tumors that is based on Transgene's myvac® technology and powered by NEC's longstanding artificial intelligence (AI) and machine learning (ML) expertise. This virus-based therapeutic vaccine encodes neoantigens (patient-specific mutations) identified and selected by NEC's Neoantigen Prediction System. The prediction system is based on more than two decades of expertise in AI and has been trained on proprietary data allowing it to accurately prioritize and select the most immunogenic is designed to stimulate the immune system of patients in order to induce a T-cell response that is able to recognize and destroy tumor cells based on their own neoantigens. This individualized immunotherapy is developed and produced for each patient. Positive data have been generated in the adjuvant setting of head and neck cancer (NCT04183166). A Phase II part is ongoing, Transgene is preparing an additional trial in a second indication, with aim to initiate the trial in Q4 2025. About the Phase I/II clinical trialTG4050 is being evaluated in a Phase I/II clinical trial for patients with HPV-negative head and neck cancers (NCT04183166). An individualized treatment is created for each patient after they complete surgery and while they receive adjuvant therapy. Half of the participants received their vaccine immediately after completing adjuvant treatment. The other half were given TG4050 as an additional treatment at the time of recurrence of the disease as an additional treatment to standard of care (SoC). This randomized study is evaluating the treatment benefits of TG4050 in patients who are at risk of relapse. In the Phase I part, thirty-two evaluable patients have been included. The Phase II part is ongoing internationally. Overall approximately 80 patients will be randomized in the trial. DisclaimerThis press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque') section of the Universal Registration Document, available on the AMF website ( or on Transgene's website ( Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. Attachment 20250619_Completion_ENError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
